News and Announcements
Revolutionary New Arthritis Treatment from Jardine Pharmaceuticals
- Published April 09, 2015 10:46AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
There is a basic human desire to relieve pain and prolong life, which fuels the search for effective medications. Most drugs come from nature and more than half of the world’s population still rely entirely on plants for their medicines.
Oak is used traditionally for treatment of arthritis. Pharmaceutical efficacy is now achieved through a proprietary extraction process for oak, beating arthritis drugs. The TGA listed oak Polypill™ capsules will be launched through existing distribution networks (Q4 2014).
Jardine Pharmaceuticals has the exclusive worldwide licence for modified polyphenol oak extracts in a complementary medicine format.
Jardine Pharmaceuticals is raising capital to fund further product/market development and research.
Yesterday, Jardine Pharmaceuticals were featured on Current Affair. To watch the video, please click the image below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
